Alps Advisors Inc. lowered its holdings in shares of Stryker Corporation (NYSE:SYK) by 10.3% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,278 shares of the medical technology company’s stock after selling 378 shares during the period. Alps Advisors Inc.’s holdings in Stryker Corporation were worth $466,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of the company. Candriam Luxembourg S.C.A. grew its position in Stryker Corporation by 0.9% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 47,796 shares of the medical technology company’s stock worth $6,788,000 after acquiring an additional 446 shares during the last quarter. Brown Advisory Securities LLC grew its position in Stryker Corporation by 8.1% during the 3rd quarter. Brown Advisory Securities LLC now owns 12,756 shares of the medical technology company’s stock worth $1,811,000 after acquiring an additional 959 shares during the last quarter. Bessemer Group Inc. grew its position in Stryker Corporation by 756.6% during the 3rd quarter. Bessemer Group Inc. now owns 39,566 shares of the medical technology company’s stock worth $5,620,000 after acquiring an additional 34,947 shares during the last quarter. Advantus Capital Management Inc grew its position in Stryker Corporation by 4.2% during the 3rd quarter. Advantus Capital Management Inc now owns 32,693 shares of the medical technology company’s stock worth $4,643,000 after acquiring an additional 1,316 shares during the last quarter. Finally, Bradley Foster & Sargent Inc. CT grew its position in Stryker Corporation by 1.0% during the 3rd quarter. Bradley Foster & Sargent Inc. CT now owns 44,514 shares of the medical technology company’s stock worth $6,322,000 after acquiring an additional 445 shares during the last quarter. 74.20% of the stock is owned by institutional investors.

In related news, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $155.34, for a total transaction of $776,700.00. Following the completion of the sale, the insider now directly owns 83,207 shares of the company’s stock, valued at $12,925,375.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 7.40% of the company’s stock.

WARNING: This piece of content was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/11/21/stryker-corporation-syk-shares-sold-by-alps-advisors-inc.html.

Shares of Stryker Corporation (NYSE:SYK) opened at $154.75 on Tuesday. The company has a market capitalization of $58,156.52, a P/E ratio of 24.63, a PEG ratio of 2.45 and a beta of 0.79. Stryker Corporation has a 52 week low of $108.29 and a 52 week high of $160.62. The company has a quick ratio of 1.61, a current ratio of 2.37 and a debt-to-equity ratio of 0.63.

Stryker Corporation (NYSE:SYK) last issued its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.50 by $0.02. The firm had revenue of $3.01 billion during the quarter, compared to the consensus estimate of $2.97 billion. Stryker Corporation had a return on equity of 24.11% and a net margin of 14.67%. The company’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same period in the prior year, the business posted $1.39 earnings per share. equities research analysts predict that Stryker Corporation will post 6.47 EPS for the current year.

SYK has been the topic of a number of research reports. Piper Jaffray Companies restated an “overweight” rating and set a $148.00 price objective on shares of Stryker Corporation in a research report on Thursday, August 24th. Needham & Company LLC upgraded Stryker Corporation from an “underperform” rating to a “hold” rating in a research report on Friday, August 25th. Robert W. Baird upgraded Stryker Corporation from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $161.00 to $173.00 in a research report on Thursday, November 16th. BidaskClub lowered Stryker Corporation from a “buy” rating to a “hold” rating in a research report on Saturday, August 26th. Finally, Stifel Nicolaus boosted their price objective on Stryker Corporation from $151.00 to $158.00 and gave the stock a “buy” rating in a research report on Friday, July 28th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have issued a buy rating to the company’s stock. Stryker Corporation presently has an average rating of “Hold” and a consensus target price of $152.10.

About Stryker Corporation

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Institutional Ownership by Quarter for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.